<DOC>
	<DOCNO>NCT01258907</DOCNO>
	<brief_summary>This Phase II ( proof-of-activity ) , double-blind , placebo-controlled , randomize , multicenter study MLDL1278A ( also know BI-204 ) involve patient standard-of-care therapy atherosclerotic cardiovascular disease evidence vascular inflammation , quantify FDG-PET/CT .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Activity Intravenous MLDL1278A Patients Standard-of-Care Therapy Stable Atherosclerotic Cardiovascular Disease ( GLACIER )</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Evidence qualify vessel ( carotid aortic ) plaque inflammation Documented atherosclerotic vascular disease clinically stable least 3 month prior screen type 2 diabetes mellitus elevate cardiovascular risk Use stable dose statin therapy least 6 week prior screen . Patients must capable maintain statin therapy current dose level screen last followup visit . For patient take angiotensinconverting enzyme ( ACE ) inhibitor ( ACEI ) angiotensinreceptor blocker ( ARBs ) , nonstatin lipidmodifying therapy , thiazolidinediones , inhaled steroid , leukotriene modifying agent , use stable dose least 6 week prior screen capable continue dose duration study Occurrence cardiovascular event &lt; 6 month prior screen Pregnant , plan become pregnant study , breastfeed Clinically significant abnormal laboratory value abnormal ECG vital sign History anaphylactic reaction Newly discover Type 2 diabetes mellitus ( T2DM ) ( prior study entry ) medical treatment T2DM start &lt; 3 month prior study entry Use insulin , corticosteroid ( oral , rectal , injectable ) , immunosuppressive medication Current recent ( within 4 week prior screen ) infection , include sign , symptom serology infection , include HIV , hepatitis B C Impaired renal function History malignancy within 2 year prior screen Current lifethreatening condition vascular disease may prevent patient complete study Use investigational drug biologic within 30 day 5 halflives ( whichever longer ) prior first dose study medication Exposure substantial radiation within 12 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>BI-204</keyword>
</DOC>